July 28, 2015
Theravance Biopharma to Report Second Quarter 2015 Financial Results on August 10, 2015
July 23, 2015
Theravance Biopharma Announces Health Canada Approval for VIBATIV(R) (telavancin) for Treatment of HAP/VAP Caused by Gram-Positive Bacteria, Including MRSA
July 2, 2015
Theravance Biopharma Announces New Employment Inducement Awards
Medicines that make a difference®
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
In some instances, we partner our programs in order to accelerate timelines and better align resources.
Every day at Theravance Biopharma, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance Biopharma discovers, develops and brings important medicines to patients by: